64Cu-DOTA-Rituximab PET/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression

被引：5
|
作者：
Lee, Inki [1 ]
Lim, Ilhan [1 ,2 ,3 ,6 ]
Lee, Kyo Chul [2 ]
Kang, Hye Jin [4 ,5 ]
Lim, Sang Moo [1 ]
机构：
[1] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Nucl Med, Seoul, South Korea
[2] Korea Inst Radiol & Med Sci, Res Inst Radiol & Med Sci, Div Appl RI, Seoul, South Korea
[3] Univ Sci & Technol, Dept Radiol & Med Oncol Sci, Seoul, South Korea
[4] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea
[5] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Internal Med, Div Hematol Oncol, 75,Nowon Ro, Seoul, South Korea
[6] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Dept Nucl Med, 75,Nowon Ro, Seoul, South Korea
来源：
CLINICAL NUCLEAR MEDICINE | 2023年 / 48卷 / 02期
基金：
新加坡国家研究基金会;
关键词：
Cu-64-DOTA-rituximab; B-cell lymphoma; CD20; antigen; positron emission tomography; POSITRON-EMISSION-TOMOGRAPHY; FDG-PET;
D O I：
10.1097/RLU.0000000000004378
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Cu-64-DOTA-rituximab PET/CT was performed on a 62-year-old and a 71-year-old men diagnosed with B-cell non-Hodgkin lymphoma. Compared with F-18-FDG PET/CT, lesions could be detected more sensitively, and it was confirmed that there was no discernible Cu-64-DOTA-rituximab uptake in the tumor other than lymphoma. Cu-64-DOTA-rituximab PET/CT could be a powerful tool for the diagnosis and monitoring treatment response of lymphoma because of imaging the CD20 expression.
引用
收藏
页码：E82 / E83
页数：2
相关论文
共 50 条
  • [41] Modulation of CD20 expression in B-cell lymphomas treated with rituximab.
    Seliem, RM
    Freeman, JK
    Hasserjian, RP
    BLOOD, 2002, 100 (11) : 311B - 311B
  • [42] Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin's lymphoma
    Fischer, M.
    Gruenwald, F.
    Knapp, W. H.
    Truemper, L.
    von Schilling, C.
    Dreyling, M.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2009, 48 (06): : 215 - 220
  • [43] Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy
    Clarke, LE
    Bayerl, MG
    Ehmann, WC
    Helm, KF
    JOURNAL OF CUTANEOUS PATHOLOGY, 2003, 30 (07) : 459 - 462
  • [44] ENGINEERED TOXIN BODIES DEMONSTRATING DIRECT CELL-KILL OF CD20 EXPRESSING B-CELL NON-HODGKIN'S LYMPHOMA CELLS
    Higgins, J.
    Kim, J.
    Cunningham, C.
    Poma, E.
    EXPERIMENTAL HEMATOLOGY, 2011, 39 (08) : S67 - S67
  • [45] Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)
    Bender, Brendan C.
    Li, Chi-Chung
    Marchand, Mathilde
    Turner, David C.
    Li, Feifei
    Vadhavkar, Shweta
    Wang, Bei
    Deng, Rong
    Lu, James
    Jin, Jin
    Li, Chunze
    Yin, Shen
    Wei, Michael C.
    Chanu, Pascal
    BLOOD, 2023, 142
  • [46] Diagnostic accuracy of 89Zr-rituximab-PET/CT imaging in patients with relapsed CD20+B-Cell non-Hodgkin's lymphoma: comparison with 18FDG-PET/CT.
    Muylle, K.
    Vugts, D. J.
    Meuleman, N.
    Ghanem, G.
    Bourgeois, P.
    Vanderlinden, B.
    Van Dongen, G. A. M. S.
    Bron, D.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S240 - S240
  • [47] Diagnostic accuracy of 89Zr-rituximab-PET/CT imaging in patients with relapsed CD20+B-Cell non-Hodgkin's lymphoma: comparison with 18FDG-PET/CT.
    Muylle, K.
    Vugts, D. J.
    Meuleman, N.
    Ghanem, G.
    Bourgeois, P.
    Vanderlinden, B.
    Van Dongen, G. A. M. S.
    Bron, D.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (SUPPL 2) : 240 - 240
  • [48] C-terminal deletion mutation of CD20 is related to low CD20 expression and shortened time to progression after rituximab treatment in non-Hodgkin's lymphoma
    Terui, Yasuhito
    Mishima, Yuji
    Hatake, Kiyohiko
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3396S - 3396S
  • [49] Radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Witzig, Thomas E.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 655 - 668
  • [50] Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma
    Terui, Yasuhito
    Mishima, Yuji
    Sugimura, Natsuhiko
    Kojima, Kiyotsugu
    Sakurai, Takuma
    Mishima, Yuko
    Kuniyoshi, Ryoko
    Taniyama, Akiko
    Yokoyama, Masahiro
    Sakajiri, Sakura
    Takeuchi, Kengo
    Watanabe, Chie
    Takahashi, Shunji
    Ito, Yoshinori
    Hatake, Kiyohiko
    CLINICAL CANCER RESEARCH, 2009, 15 (07) : 2523 - 2530
12345